Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of various medicinal products. Primarily operating within the People's Republic of China, the company's research and development efforts are concentrated on a diverse range of disease areas, including oncology (cancer), metabolic conditions, autoimmune disorders, neurological ailments, and infectious diseases. Its flagship commercial offering is JS001, known by the brand name TUOYI. This recombinant humanized anti-PD-1 monoclonal antibody has received approval for treating multiple cancer indications, such as melanoma (including mucosal), soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. Beyond its marketed product, Junshi Biosciences maintains a comprehensive pipeline of investigational therapies. These include UBP1211, a biosimilar of Humira, slated for conditions like rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Also under development are JS002, a recombinant humanized anti-PCSK9 monoclonal antibody targeting hyperlipidemia, and UBP1213, an injectable recombinant humanized anti-BLyS monoclonal antibody. Additional development candidates feature JS501, a biosimilar of Avastin; JS003, an injectable recombinant humanized anti-PD-L1 monoclonal antibody; JS101, a pan-CDK inhibitor; TAB004/JS004, an injectable recombinant humanized anti-BTLA monoclonal antibody; and JS005, an injectable recombinant humanized anti-IL-17A monoclonal antibody. The company has established significant collaborations, including an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the illness caused by the SARS-CoV-2 novel coronavirus. Furthermore, it has partnered with Coherus Biosciences, Inc. for the development and commercialization of toripalimab, which is Junshi Biosciences' proprietary anti-PD-1 antibody. Founded in 2012, Shanghai Junshi Biosciences Co., Ltd. is headquartered in Shanghai, People's Republic of China.
—
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of various medicinal products. Primarily operating within the People's Republic of China, the company's research and development efforts are concentrated on a diverse range of disease areas, including oncology (cancer), metabolic conditions, autoimmune disorders, neurological ailments, and infectious diseases. Its flagship commercial offering is JS001, known by the brand name TUOYI. This recombinant humanized anti-PD-1 monoclonal antibody has received approval for treating multiple cancer indications, such as melanoma (including mucosal), soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. Beyond its marketed product, Junshi Biosciences maintains a comprehensive pipeline of investigational therapies. These include UBP1211, a biosimilar of Humira, slated for conditions like rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Also under development are JS002, a recombinant humanized anti-PCSK9 monoclonal antibody targeting hyperlipidemia, and UBP1213, an injectable recombinant humanized anti-BLyS monoclonal antibody. Additional development candidates feature JS501, a biosimilar of Avastin; JS003, an injectable recombinant humanized anti-PD-L1 monoclonal antibody; JS101, a pan-CDK inhibitor; TAB004/JS004, an injectable recombinant humanized anti-BTLA monoclonal antibody; and JS005, an injectable recombinant humanized anti-IL-17A monoclonal antibody. The company has established significant collaborations, including an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the illness caused by the SARS-CoV-2 novel coronavirus. Furthermore, it has partnered with Coherus Biosciences, Inc. for the development and commercialization of toripalimab, which is Junshi Biosciences' proprietary anti-PD-1 antibody. Founded in 2012, Shanghai Junshi Biosciences Co., Ltd. is headquartered in Shanghai, People's Republic of China.
—
Daily adjusted close
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of various medicinal products. Primarily operating within the People's Republic of China, the company's research and development efforts are concentrated on a diverse range of disease areas, including oncology (cancer), metabolic conditions, autoimmune disorders, neurological ailments, and infectious diseases. Its flagship commercial offering is JS001, known by the brand name TUOYI. This recombinant humanized anti-PD-1 monoclonal antibody has received approval for treating multiple cancer indications, such as melanoma (including mucosal), soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. Beyond its marketed product, Junshi Biosciences maintains a comprehensive pipeline of investigational therapies. These include UBP1211, a biosimilar of Humira, slated for conditions like rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Also under development are JS002, a recombinant humanized anti-PCSK9 monoclonal antibody targeting hyperlipidemia, and UBP1213, an injectable recombinant humanized anti-BLyS monoclonal antibody. Additional development candidates feature JS501, a biosimilar of Avastin; JS003, an injectable recombinant humanized anti-PD-L1 monoclonal antibody; JS101, a pan-CDK inhibitor; TAB004/JS004, an injectable recombinant humanized anti-BTLA monoclonal antibody; and JS005, an injectable recombinant humanized anti-IL-17A monoclonal antibody. The company has established significant collaborations, including an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the illness caused by the SARS-CoV-2 novel coronavirus. Furthermore, it has partnered with Coherus Biosciences, Inc. for the development and commercialization of toripalimab, which is Junshi Biosciences' proprietary anti-PD-1 antibody. Founded in 2012, Shanghai Junshi Biosciences Co., Ltd. is headquartered in Shanghai, People's Republic of China.